Key statistics
As of last trade Takeda Pharmaceutical Co Ltd (TKD:FRA) traded at 25.14, 7.57% above its 52-week low of 23.37, set on Jun 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.14 |
---|---|
High | 25.14 |
Low | 25.14 |
Bid | 25.33 |
Offer | 25.56 |
Previous close | 25.12 |
Average volume | 1.52k |
---|---|
Shares outstanding | 1.59bn |
Free float | 1.59bn |
P/E (TTM) | 22.66 |
Market cap | 6.56tn JPY |
EPS (TTM) | 181.90 JPY |
Annual div (ADY) | 1.21 EUR |
---|---|
Annual div yield (ADY) | 4.82% |
Div ex-date | Sep 27 2024 |
Div pay-date | Dec 02 2024 |
Data delayed at least 15 minutes, as of Nov 22 2024 08:13 GMT.
More ▼
Press releases
- Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
- Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
- Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
- Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
- Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
- Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
- Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
- Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
More ▼